• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名肺腺癌患者出现异常延长的培美曲塞细胞毒性:病例报告

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.

作者信息

Sakhri Linda, Pinsolle Julian, Moro-Sibilot Denis, Pluchart Hélène

机构信息

Institut de Cancérologie Daniel Hollard, Groupe Hospitalier Mutualiste, 124 rue d'Alembert, 38000, Grenoble, France.

UM Oncologie Thoracique, Clinique de pneumologie, Pôle Thorax et vaisseaux, Centre Hospitalier Universitaire Michallon, BP217, 38043, Grenoble cedex 9, France.

出版信息

J Med Case Rep. 2017 Sep 16;11(1):262. doi: 10.1186/s13256-017-1436-7.

DOI:10.1186/s13256-017-1436-7
PMID:28915906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5603063/
Abstract

BACKGROUND

We describe a case of pemetrexed toxicities related to reabsorption by an ileal neobladder, which caused prolonged hematotoxicity and nephrotoxicity.

CASE PRESENTATION

A 59-year-old white man was diagnosed with metastatic wild-type adenocarcinoma of the upper lobe of his right lung. After a first cycle of cisplatin and pemetrexed, he had unusually prolonged aplasia and acute kidney injury. The prolonged aplasia was caused by pemetrexed reabsorption by the ileal mucosa of the neobladder as pemetrexed was eliminated renally in an active form and is partly lipophilic.

CONCLUSIONS

Pemetrexed may be reabsorbed by the ileal mucosa of the neobladder because of its hydrophobic structure and renal excretion in its active form. Acute urinary retention may maintain this phenomenon. Published data excluded a potential role for cisplatin in this toxicity; furthermore, we could not assess pemetrexed concentrations in the blood or urine as these assay techniques are not validated. Thus, care is needed when giving chemotherapy to patients with a neobladder.

摘要

背景

我们描述了一例培美曲塞毒性反应,该反应与回肠新膀胱的重吸收有关,导致了长期的血液毒性和肾毒性。

病例介绍

一名59岁白人男性被诊断为右肺上叶转移性野生型腺癌。在接受顺铂和培美曲塞的第一个周期治疗后,他出现了异常延长的再生障碍和急性肾损伤。延长的再生障碍是由于培美曲塞被新膀胱的回肠黏膜重吸收所致,因为培美曲塞以活性形式经肾脏排泄且部分具有亲脂性。

结论

由于培美曲塞的疏水结构及其以活性形式经肾脏排泄,它可能被新膀胱的回肠黏膜重吸收。急性尿潴留可能会维持这种现象。已发表的数据排除了顺铂在这种毒性反应中的潜在作用;此外,由于这些检测技术未经验证,我们无法评估血液或尿液中的培美曲塞浓度。因此,对有新膀胱的患者进行化疗时需要谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72dc/5603063/7c007c33a0a5/13256_2017_1436_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72dc/5603063/6216843476b6/13256_2017_1436_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72dc/5603063/c039e0a73516/13256_2017_1436_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72dc/5603063/7c007c33a0a5/13256_2017_1436_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72dc/5603063/6216843476b6/13256_2017_1436_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72dc/5603063/c039e0a73516/13256_2017_1436_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72dc/5603063/7c007c33a0a5/13256_2017_1436_Fig3_HTML.jpg

相似文献

1
Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.一名肺腺癌患者出现异常延长的培美曲塞细胞毒性:病例报告
J Med Case Rep. 2017 Sep 16;11(1):262. doi: 10.1186/s13256-017-1436-7.
2
Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature.培美曲塞引起的导致停药的肾损伤:一例病例报告及文献复习
J Med Case Rep. 2017 Jul 28;11(1):182. doi: 10.1186/s13256-017-1348-6.
3
Prolonged survival with maintenance pemetrexed for a multiple primary malignancy.培美曲塞维持治疗对多原发性恶性肿瘤的长期生存作用
BMJ Support Palliat Care. 2019 Mar;9(1):51-53. doi: 10.1136/bmjspcare-2018-001559. Epub 2018 May 18.
4
Pemetrexed-induced acute kidney injury leading to chronic kidney disease.培美曲塞诱导的急性肾损伤导致慢性肾脏病。
Clin Nephrol. 2014 Dec;82(6):402-6. doi: 10.5414/CN107921.
5
Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report.培美曲塞诱发肺癌患者严重横纹肌溶解症:一例报告
J Oncol Pharm Pract. 2019 Dec;25(8):2007-2009. doi: 10.1177/1078155218816767. Epub 2018 Nov 30.
6
Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.肺腺癌患者接受培美曲塞治疗后出现再生障碍性贫血。
Invest New Drugs. 2017 Oct;35(5):662-664. doi: 10.1007/s10637-017-0462-z. Epub 2017 Mar 30.
7
[Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin 
in Patients with IIIa Lung Adenocarcinoma].新辅助贝伐单抗联合培美曲塞和顺铂治疗Ⅲa期肺腺癌患者的安全性
Zhongguo Fei Ai Za Zhi. 2015 Jun;18(6):365-8. doi: 10.3779/j.issn.1009-3419.2015.06.06.
8
[A case of Carboplatin and pemetrexed combination chemotherapy for synchronous double cancers of hepatocellular carcinoma and primary lung cancer].[卡铂与培美曲塞联合化疗治疗肝细胞癌和原发性肺癌同步双癌1例]
Gan To Kagaku Ryoho. 2014 Nov;41(12):2154-6.
9
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.18F-氟代脱氧葡萄糖正电子发射断层扫描在评估复发非小细胞肺癌患者对纳武单抗的反应中的应用
World J Surg Oncol. 2016 Sep 5;14(1):238. doi: 10.1186/s12957-016-0998-y.
10
Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.晚期非鳞状非小细胞肺癌患者在顺铂、培美曲塞和贝伐珠单抗诱导治疗后行多西他赛和贝伐珠单抗维持治疗的 II 期研究。
Med Oncol. 2018 Jun 16;35(7):108. doi: 10.1007/s12032-018-1172-x.

本文引用的文献

1
Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).培美曲塞联合顺铂治疗晚期尿路上皮癌的II期研究:PECULIAR研究(KCSG 10-17)
Br J Cancer. 2015 Jan 20;112(2):260-5. doi: 10.1038/bjc.2014.591. Epub 2014 Nov 27.
2
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.一项III期研究,比较顺铂加吉西他滨与顺铂加培美曲塞用于初治晚期非小细胞肺癌患者的化疗效果。
J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
3
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
培美曲塞二钠与吉西他滨用于晚期尿路上皮癌的2期试验(E4802):东部肿瘤协作组的一项试验
Cancer. 2008 Jun 15;112(12):2671-5. doi: 10.1002/cncr.23503.
4
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.吉西他滨/顺铂/培美曲塞三联疗法用于转移性尿路上皮移行细胞癌患者的I期研究。
Invest New Drugs. 2008 Apr;26(2):151-8. doi: 10.1007/s10637-007-9111-2. Epub 2008 Jan 31.
5
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.培美曲塞作为转移性尿路上皮癌患者二线治疗的II期试验。
Invest New Drugs. 2007 Jun;25(3):265-70. doi: 10.1007/s10637-006-9020-9. Epub 2006 Dec 5.
6
Molecular mechanisms of resistance and toxicity associated with platinating agents.与铂类药物相关的耐药性和毒性的分子机制。
Cancer Treat Rev. 2007 Feb;33(1):9-23. doi: 10.1016/j.ctrv.2006.09.006. Epub 2006 Nov 3.
7
A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.培美曲塞联合吉西他滨治疗局部晚期和/或转移性尿路上皮移行细胞癌的II期试验。
Ann Oncol. 2006 Oct;17(10):1533-8. doi: 10.1093/annonc/mdl154. Epub 2006 Jul 27.
8
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.培美曲塞用于尿路上皮移行细胞癌二线治疗的II期研究。
J Clin Oncol. 2006 Jul 20;24(21):3451-7. doi: 10.1200/JCO.2005.03.6699.
9
Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs.膀胱内注射培美曲塞的潜力与毒性:猪的临床前研究
Clin Cancer Res. 2006 Apr 15;12(8):2597-601. doi: 10.1158/1078-0432.CCR-05-2644.
10
FDA drug approval summaries: pemetrexed (Alimta).美国食品药品监督管理局药物批准摘要:培美曲塞(力比泰)。
Oncologist. 2004;9(5):482-8. doi: 10.1634/theoncologist.9-5-482.